Author:
Ye Peng,Wang Yiran,Li Ruiqi,Chen Wanlu,Wan Lu,Cai Peiling
Reference191 articles.
1. Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3-neutralizing human antibody SAR256212 in patients with solid tumors;Abramson;Clin. Res.,2017
2. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial;Adams;Lancet Gastroenterol. Hepatol.,2018
3. Phase II trial of trametinib and panitumumab in RAS/RAF wild type metastatic colorectal cancer;Alshammari;Clin. Colorectal Cancer,2021
4. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer;Amado;J. Clin. Oncol.,2008
5. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells;Amin;Biochem. J.,2012
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献